Binding Agents Binding to PD-L1 and CD137 and Use Thereof
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application PCT/EP2018/071002, filed Aug 2, 2018. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,968,280 | Binding Agents Binding to PD-L1 and CD137 and Use Thereof In force · High confidence | Genmab A/S | In force | High confidence | ||
| US 11,459,395 | Binding Agents Binding to PD-L1 and CD137 and Use Thereof In force · High confidence | Genmab A/S | In force | High confidence | ||
| US 12,570,751 | Binding Agents Binding to PD-L1 and CD137 and Use Thereof In force · Medium confidence | Genmab A/S | In force | Medium confidence | ||
| US 12,637,515 | Binding Agents Binding to PD-L1 and CD137 and Use Thereof In force · Medium confidence | Genmab A/S | In force | Medium confidence | ||
| Application 17/821,837 | Binding Agents Binding to PD-L1 and CD137 and Use Thereof Abandoned Abandoned Oct 30, 2026 | Genmab A/S | Abandoned | Abandoned Oct 30, 2026 |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by Genmab A/S.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.